CY Cheah, E Zucca, D Rossi, TM Habermann - Haematologica, 2022 - ncbi.nlm.nih.gov
Marginal zone lymphomas (MZL) are collectively the second most common indolent lymphoma comprising 7% of all non-Hodgkin lymphomas with 7,460 patients diagnosed in …
E Son, A Panwar, CH Mosher, D Lydiatt - Journal of oncology practice, 2018 - ascopubs.org
Salivary gland malignancies are rare tumors that comprise multiple histologic entities with diverse clinical behavior. Mucoepidermoid carcinoma is the most frequent primary salivary …
CY Cheah, JF Seymour - American Journal of Hematology, 2023 - Wiley Online Library
Disease overview Marginal zone lymphomas (MZL) are collectively the second most common type of indolent lymphoma. Diagnosis Three subtypes of MZL are recognized …
SY Kim, U Borner, JH Lee, F Wagner… - BMC medical …, 2022 - Springer
Imaging of parotid gland tumors is challenging due to the wide variety of differential diagnoses. Malignant parotid tumors can have very similar features to benign ones, such as …
I Defrancesco, L Arcaini - Best Practice & Research Clinical Haematology, 2018 - Elsevier
Extranodal marginal zone B-cell lymphomas (EMZLs) of the mucosa-associated lymphoid tissue (MALT) are indolent lymphomas which can present at any extranodal site. The most …
The field of haematopathology is rapidly evolving and for the non-specialized pathologist receiving a specimen with the possibility of a lymphoid malignancy may be a daunting …
D Di Santo, C Bramati, BM Festa, GM Pace… - European Archives of …, 2023 - Springer
Background and purpose Parotid gland lymphoma (PGL) is a rare and challenging diagnosis. Different lymphomas can develop in the parotid gland, with the most common …
This expert volume in the Diagnostic Pathology series is an excellent point-of-care resource for practitioners at all levels of experience and training. Covering all aspects of benign and …
J Rocca, M Beydon, V Le Guern, E Hachulla… - The Lancet …, 2024 - thelancet.com
Background Sjögren's disease is the autoimmune disease with the highest risk of lymphoma development. There is no consensus on the optimal way to manage Sjögren's disease …